MYBPC3 and cardiac hypertrophy: Therefore, as the knowledge of mitral valve length in clinical and subclinical HCM is quite limited, the aim of the present study was to investigate mitral valve leaflet length in carriers of the single MYBPC3-Q1016X mutation, with and without LVH and mutation negative relatives without hypertrophy by CMR.